David Grimwade Selected Research

David Grimwade Research Topics

Disease

28	Acute Promyelocytic Leukemia 01/2018 - 08/2002
17	Leukemia 01/2018 - 08/2002
16	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 05/2002
13	Residual Neoplasm 01/2018 - 03/2002
7	Neoplasms (Cancer) 02/2016 - 10/2005
4	Genetic Translocation (Chromosomal Translocation) 01/2010 - 04/2005
2	Hematologic Neoplasms (Hematological Malignancy) 11/2015 - 03/2014
2	Breast Neoplasms (Breast Cancer) 01/2010 - 10/2008
2	Multiple Sclerosis 03/2009 - 10/2008
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021
1	Carcinogenesis 11/2015
1	Alopecia (Baldness) 10/2015
1	Chromosome Breakage 03/2014
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2009
1	Hemorrhage 02/2009
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 12/2008
1	Myocardial Infarction 12/2008
1	Eosinophilia 06/2007
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2007
1	Pdgfra-Associated Chronic Eosinophilic Leukemia 06/2007
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2006
1	Laryngeal Neoplasms (Laryngeal Cancer) 04/2005
1	Hypersensitivity (Allergy) 08/2002

Drug/Important Bio-Agent (IBA)

10	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2018 - 11/2007
5	Oncogene Proteins (Oncogene Protein)IBA 01/2018 - 04/2005
5	Arsenic Trioxide (Trisenox)FDA Link 10/2015 - 02/2009
5	Mitoxantrone (Novantrone)FDA LinkGeneric 03/2014 - 04/2005
5	Type II DNA Topoisomerases (Topoisomerase II)IBA 03/2014 - 04/2005
4	AnthracyclinesIBA 01/2018 - 08/2009
4	Retinoic Acid Receptor alphaIBA 12/2009 - 02/2003
3	RetinoidsIBA 01/2011 - 10/2005
3	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 01/2010 - 03/2002
3	Imatinib Mesylate (Gleevec)FDA Link 12/2008 - 07/2006
2	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 01/2018 - 03/2014
2	Protein Isoforms (Isoforms)IBA 11/2015 - 02/2008
2	PoisonsIBA 03/2014 - 04/2005
2	Epirubicin (Ellence)FDA LinkGeneric 03/2014 - 01/2010
2	ChromatinIBA 12/2009 - 08/2002
2	Proteins (Proteins, Gene)FDA Link 12/2009 - 01/2009
2	DNA (Deoxyribonucleic Acid)IBA 03/2009 - 04/2005
1	Indicators and Reagents (Reagents)IBA 01/2018
1	Nuclear Matrix-Associated ProteinsIBA 11/2017
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2016
1	NucleophosminIBA 02/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 11/2015
1	Alanine Transaminase (SGPT)IBA 10/2015
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 10/2015
1	fms-Like Tyrosine Kinase 3IBA 12/2014
1	MicroRNAs (MicroRNA)IBA 03/2014
1	Etoposide (VP 16)FDA LinkGeneric 03/2014
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2014
1	Messenger RNA (mRNA)IBA 05/2010
1	trioctyl phosphine oxide (TOPO)IBA 03/2009
1	cellular retinoic acid binding protein IIBA 11/2007
1	Tyrosine Kinase InhibitorsIBA 07/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2005
1	Phosphodiesterase InhibitorsIBA 10/2005
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 10/2005
1	Retinoid X Receptors (Retinoid X Receptor)IBA 10/2005
1	LigandsIBA 10/2005
1	Death Domain ReceptorsIBA 10/2005
1	Initiator CaspasesIBA 10/2005
1	Deoxyribonuclease I (Nickase)IBA 08/2002
1	Core Binding Factors (Core-Binding Factor)IBA 05/2002

Therapy/Procedure

24	Therapeutics 01/2021 - 04/2005
7	Drug Therapy (Chemotherapy) 01/2018 - 08/2009
3	Aftercare (After-Treatment) 03/2009 - 04/2005
1	Cell Transplantation 01/2020
1	Stem Cell Transplantation 01/2020
1	Transcutaneous Electric Nerve Stimulation (TENS) 01/2011
1	Salvage Therapy 02/2009